UNITED LAB Shares Rise Nearly 3% as Its Self-Developed Innovative Drug UBT251 Injection Receives Clinical Trial Implied Permission for OSA Indication

Stock News

Feb 05

Shares of UNITED LAB (03933) climbed close to 3%. At the time of writing, the stock was up 2.7%, trading at HK$12.17, with a turnover of HK$54.12 million.

The increase follows an announcement from the company stating that on February 2, 2026, its wholly-owned subsidiary, Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., received implied permission from China's National Medical Products Administration for clinical trials of its self-developed Class 1 innovative drug, UBT251 injection, for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity.

As China's first chemically synthesized novel drug acting as a GLP-1/GIP/GCG triple-target receptor agonist, UBT251 positions the company significantly within the research domain of such therapeutics.

Moving forward, the company remains committed to the research and development of new products, with a strategic focus on enhancing its competitiveness and innovation capacity in the biopharmaceutical industry, which is anticipated to generate greater returns for the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1129160772"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129160772\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129160772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 10:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129160772","market":"nz","top_or_hot":-1,"title":"UNITED LAB Shares Rise Nearly 3% as Its Self-Developed Innovative Drug UBT251 Injection Receives Clinical Trial Implied Permission for OSA Indication","media":"Stock News","content":"<p>Shares of UNITED LAB (03933) climbed close to 3%. At the time of writing, the stock was up 2.7%, trading at HK$12.17, with a turnover of HK$54.12 million.</p>\n<p>The increase follows an announcement from the company stating that on February 2, 2026, its wholly-owned subsidiary, Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., received implied permission from China's National Medical Products Administration for clinical trials of its self-developed Class 1 innovative drug, UBT251 injection, for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity.</p>\n<p>As China's first chemically synthesized novel drug acting as a GLP-1/GIP/GCG triple-target receptor agonist, UBT251 positions the company significantly within the research domain of such therapeutics.</p>\n<p>Moving forward, the company remains committed to the research and development of new products, with a strategic focus on enhancing its competitiveness and innovation capacity in the biopharmaceutical industry, which is anticipated to generate greater returns for the company and its shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB Shares Rise Nearly 3% as Its Self-Developed Innovative Drug UBT251 Injection Receives Clinical Trial Implied Permission for OSA Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB Shares Rise Nearly 3% as Its Self-Developed Innovative Drug UBT251 Injection Receives Clinical Trial Implied Permission for OSA Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-05 10:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of UNITED LAB (03933) climbed close to 3%. At the time of writing, the stock was up 2.7%, trading at HK$12.17, with a turnover of HK$54.12 million.</p>\n<p>The increase follows an announcement from the company stating that on February 2, 2026, its wholly-owned subsidiary, Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., received implied permission from China's National Medical Products Administration for clinical trials of its self-developed Class 1 innovative drug, UBT251 injection, for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity.</p>\n<p>As China's first chemically synthesized novel drug acting as a GLP-1/GIP/GCG triple-target receptor agonist, UBT251 positions the company significantly within the research domain of such therapeutics.</p>\n<p>Moving forward, the company remains committed to the research and development of new products, with a strategic focus on enhancing its competitiveness and innovation capacity in the biopharmaceutical industry, which is anticipated to generate greater returns for the company and its shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"","article_id":"1129160772","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129160772","pubTimestamp":1770260215,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of UNITED LAB (03933) climbed close to 3%. At the time of writing, the stock was up 2.7%, trading at HK$12.17, with a turnover of HK$54.12 million. The increase follows an announcement from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","VXUS":"国际股票ETF-Vanguard","06978":"永泰生物-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1191":"制药","VT":"世界全股市ETF-Vanguard","BK1574":"生物医药B类股","03933":"联邦制药"},"translate_title":"联邦制药股价涨近3%，自研创新药UBT251注射液获OSA适应症临床试验默示许可","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"03933":1,"VT":1,"VXUS":1,"06978":1},"content_text":"Shares of UNITED LAB (03933) climbed close to 3%. At the time of writing, the stock was up 2.7%, trading at HK$12.17, with a turnover of HK$54.12 million.\nThe increase follows an announcement from the company stating that on February 2, 2026, its wholly-owned subsidiary, Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., received implied permission from China's National Medical Products Administration for clinical trials of its self-developed Class 1 innovative drug, UBT251 injection, for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity.\nAs China's first chemically synthesized novel drug acting as a GLP-1/GIP/GCG triple-target receptor agonist, UBT251 positions the company significantly within the research domain of such therapeutics.\nMoving forward, the company remains committed to the research and development of new products, with a strategic focus on enhancing its competitiveness and innovation capacity in the biopharmaceutical industry, which is anticipated to generate greater returns for the company and its shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}